Carbohydrate-based Cardiovascular Glycomedicine Development

Carbohydrate-based Cardiovascular Glycomedicine Development

CD BioGlyco is a world-leading independent biotechnology company, focusing on high-quality innovative services related to glycobiology. CD BioGlyco has professional glycomedicine development teams with multiple world-leading technologies to help customers comprehensively promote the development of carbohydrate-based cardiovascular glycomedicine.

Cardiovascular Diseases and Carbohydrate-based Antithrombotic Drugs

Cardiovascular diseases (CVD) represent one of the most frequent causes of death globally. Under pathologic conditions, thrombosis or thromboembolism blocks the natural blood flow, leading to related organ dysfunction, including ischemic stroke, peripheral artery disease, and ischemic heart disease consisting of chronic coronary artery disease and acute coronary syndrome. Therefore, antithrombotic therapy, including anticoagulant therapy, antiplatelet therapy, and thrombolytic therapy, is widely applied in these scenarios and regarded as the cornerstone of CVD therapy.

Carbohydrate-based drugs occupy an unshakable position in the field of antithrombotic therapy. The earliest natural anticoagulant heparin was discovered in dog liver in 1916, and belongs to the glycosaminoglycan polysaccharide family. Importantly, a rare pentasaccharide unit of heparin binds strongly to antithrombin III to mediate the robust anticoagulant effects. In addition, the purinergic receptor P2Y12, which is stimulated by ADP but inhibited by ATP, plays an important role in platelet hemostasis. Therefore, some adenine nucleotide analogs own antiplatelet effects.

Fig.1 Schematic representation of novel antithrombotic approaches.Fig.1 Schematic representation of novel antithrombotic approaches. (Mcfadyen & Peter,2017)

Carbohydrate-based Cardiovascular Glycomedicine Development Services

CD BioGlyco has developed a powerful carbohydrate-based glycomedicine development platform and various systematic solutions for the development of carbohydrate-based cardiovascular glycomedicine. CD BioGlyco provides carbohydrate-based antiplatelet glycomedicine development service and the antiplatelet activity can be determined.

Advantages of Us

  • A professional team specializes in glycomedicine development.
  • Cutting-edge technology.
  • Efficient, fast, and practical service.
  • Detailed and reliable after-sales service.

With a first-class experimental platform and professional research teams, CD BioGlyco is committed to ensuring customer the highest level of satisfaction. Our professional research teams provide customers with high-quality carbohydrate-based cardiovascular glycomedicine development services according to their needs. If you are interested in our services, please contact us to obtain more information.


  1. Mcfadyen, J.D.; Peter, K. Novel antithrombotic drugs on the horizon: The ultimate promise to prevent clotting while avoiding bleeding. Circulation Research. 2017, 121(10): 1133-1135.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.